Related Experiment Video

Updated: Jan 4, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Veliparib overcomes multidrug resistance in liver cancer cells

Lin Chang1, Yulan Hou1, Lili Zhu1

  • 1Department of Laboratory Medicine, Bishan Hospital, Chongqing, China.

Biochemical and Biophysical Research Communications
|November 5, 2019
PubMed

Insights

Veliparib, a PARP inhibitor, can overcome multidrug resistance (MDR) in liver cancer by enhancing chemotherapy drug accumulation and inhibiting ABCB1 transporter activity. This suggests combining veliparib with chemotherapy may benefit liver cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Multidrug resistance (MDR) in cancer, driven by ATP-binding cassette (ABC) transporters, limits chemotherapy efficacy.
  • ABCB1 transporter overexpression is a key factor in the progression of various cancers, including liver cancer.

Purpose of the Study:

  • To investigate if veliparib, a PARP inhibitor, can overcome ABCB1-mediated MDR in liver cancer cells.
  • To explore the potential of veliparib in combination therapy for liver cancer.

Main Methods:

  • Utilized liver cancer cells overexpressing ABCB1.
  • Assessed the cytotoxic effects of veliparib combined with chemotherapeutic drugs.
  • Measured doxorubicin accumulation in cancer cells.
  • Evaluated the effect of veliparib on ABCB1 transporter ATPase activity.

Main Results:

  • Veliparib significantly enhanced the cytotoxic effects of chemotherapeutic drugs in ABCB1-overexpressing liver cancer cells.
  • Veliparib increased doxorubicin accumulation without altering ABCB1 expression levels.
  • Veliparib demonstrated significant inhibition of ABCB1 transporter ATPase activity.

Conclusions:

  • Veliparib can overcome ABCB1-mediated multidrug resistance in liver cancer.
  • Combining veliparib with conventional chemotherapeutic drugs may offer a promising therapeutic strategy for liver cancer patients.
  • Veliparib's mechanism involves enhancing drug accumulation and inhibiting ABCB1 transporter function.
Keywords:
ABC transporterLiver cancerMultidrug resistance (MDR)Veliparib

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.4K
Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

39.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
223
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K